Inflammatory bowel diseases: clinical update of practical guidelines

Nuclear Medicine Communications

Volumn 26, Issue 7, 2005, Pages 649-655

  Viscido, Angelo ^a   Aratari, Annalisa ^b   Maccioni, Francesca ^b   Signore, Alberto ^b   Caprilli, Renzo ^b  

^a Nuclear Medicine Unit   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CORTICOSTEROID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB;

ABDOMINAL RADIOGRAPHY; BARIUM ENEMA; CLINICAL PROTOCOL; CLINICAL TRIAL; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC VALUE; ECHOGRAPHY; FLUOROSCOPY; GENE INTERACTION; HUMAN; IMMUNE RESPONSE; INTESTINE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; DIAGNOSTIC IMAGING; HUMANS; INFLAMMATORY BOWEL DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 21344464242     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000169205.21377.6a     Document Type: Article

References (36)

1. Kirsner JB. Nonspecific inflammatory bowel disease (ulcerative colitis and Crohn's disease) after 100 years - what next? Ital J Gastroenterol Hepatol 1999; 31:651-658.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182-205.
3. Caprilli R, Viscido A. Evolving concepts on inflammatory bowel disease. Are we happy with the present nosology? Ital J Gastroenterol Hepatol 1999; 31:893-897.
4. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inibitors. Gastroenterology 2000; 119:1148-1157.
5. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al. Increased production of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39:684-689.
6. Cominelli F. Tumor necrosis factor modulation: from bench to bedside. Inflam Bowel Dis 2000; 6:S21-S22.
7. Goodnow C. Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 2001; 357:2115-2121.
8. Eigler A, Sinha B, Hartman G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18:487-492.
9. Lugering A, Schmidt M, Lugering N, Paules HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121:1145-1157.
10. Van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121:1242-1246.
11. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory disease: a review of agents, pharmacology, clinical results, and safety. Inflam Bowel Dis 1999; 5:119-133.
12. Westermann B, Engelhardt B, Hoffmann JC. Migration of T-cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med 2001; 135:279-295.
13. Tak PP, Firestein GS. NF-kB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11.
14. Mercurio F, Zhu H, Murray BW, Shevchenco A, et al. Cytokine-activated IKB kinases essential for NFKB activation. Science 1997; 278:860-866.
15. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. Am Soc Biochem Mol Biol 1995; 270:16483-16486.
16. Healy JI, Goodnow CC. Positive versus negative signalling by lymphocyte antigen receptors. Annu Rev Immunol 1998; 16:645-670.
17. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
18. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
19. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod17APAF-1 family member that is restricted to monocytes and activates NF-kB. J Biol Chem 2001; 276:4812-4818.
20. Cho H. The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease. Inflam Bowel Dis 2001; 7:271-275.
21. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359:331-340.
22. Shanahan F. Crohn's disease. Lancet 2002; 359:62-69.
23. Sands BE. Biologic therapy for inflammatory bowel disease. Inflam Bowel Dis 1997; 3:95-113.
24. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with Infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European Multicenter Trial. Gastroenterology 1999; 116:1029-1034.
25. D'Haens G. Infliximab (Remicade): is it the magic bullet for Crohn's disease?. Dig Liver Dis 2000; 32:653-656.
26. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
27. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885.
28. Rampton DS. Management of Crohn's disease. BMJ 1999; 319:1480-1485.
29. Kornbluth A, Legnani P, Lewis BS. Video capsule endoscopy in inflammatory bowel diseases: past, present, and future. Inflam Bowel Dis 2004; 10:278-285.
30. Signore A, Annovazzi A, Chianelli M, Corsetti F, Van de Wiele C, Watherhouse RN. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001; 28:1555-1565.
31. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000; 41:242-249.
32. 99mTc-interleukin-2 and (99)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging 2003; 30:374-382.
33. Bhatti M, Chapman P, Peters M, Haskard D, Hodgson HJ. Visualising E-selectin in the detection and evaluation of inflammatory bowel disease. Gut 1998; 43:40-47.
34. Rapaccini GL, Pompili M, Orefice R, Covino M, Riccardi L, Cedrone A, et al. Contrast-enhanced power doppler of intestinal wall in the evaluation of patients with Crohn's disease. Scand J Gastroenterol 2004; 39:188-194.
35. Pallotta N, Baccini F, Corazziari E. Small intestine contrast ultrasonography (SICUS) in the diagnosis of small intestine lesions. Ultrasound Med Biol 2001; 27:335-341.
36. Maccioni F, Viscido A, Broglia L, Marrollo M, Masciangelo R, Caprilli R, et al. Evaluation of Crohn disease activity with magnetic resonance imaging. Abdom Imaging 2000; 25:219-228.